News for SYNAPTOGENIX INC (SNPXD)

PR NewswireNEW YORK, Dec. 20, 2024 $19.6 million in cash and cash equivalents as of September 30, 2024Dramatically reduced cash burn rate expected NEW YORK

Synaptogenix stock hits 52-week low at $2.71 amid market challenges

Synaptogenix appoints new auditor as Morison Cogen exits

Synaptogenix stock hits 52-week low at $3.17 amid market challenges

Synaptogenix secures $5 million in preferred stock financing

Israel-based thermal energy business Brenmiller Energy Ltd (BNRG) is up over 122 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Synaptogenix regains Nasdaq listing compliance

Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. , an emerging biopharmaceutical company...

Synaptogenix announces reverse stock split to regain Nasdaq compliance

Shares of Etsy, Inc.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.31%

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.85%

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 400 points on Friday.

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.